

# BARBADOS NATIONAL ACTION PLAN ON COMBATTING ANTIMICROBIAL RESISTANCE 2017-2022

---

**MINISTRY OF HEALTH, BARBADOS**

*5/17/2017*

## Foreword

The rise in antimicrobial resistance has been described as one of the most alarming trends that threatens the future use of antimicrobial agents. Antimicrobial resistance is now a serious problem in all areas of infectious diseases including viral, bacterial, fungal and parasitic diseases. Because of the lack of systematic surveillance, this public health problem has only recently been emphasised.

Following the approval of the Global Action Plan for Antimicrobial Resistance at the 68<sup>th</sup> World Health Assembly in May 2015 and the subsequent high-level meeting of the UN General Assembly on Antimicrobial Resistance held in September 2016 which called for national, regional and international political commitment to addressing the issue, Member States agreed on the importance of moving forward to develop national action plans by May 2017.

The Barbados National Action Plan on Combatting Antimicrobial Resistance 2017-2022 was therefore produced with this target in mind. This action plan is a product of multi-sectoral collaboration among national stakeholders. As with almost all health care interventions, sharing the responsibility with other sectors has proven to be essential to achieving desired outcomes. I am therefore pleased that the Ministry of Health will take the lead in this initiative. I must make mention however, of the strategically chosen oversight committee comprising of but not limited to representatives from Surveillance, Health Promotion, Infection Prevention and Control, Drug Service, Laboratories, Agriculture, Customs, Commerce, Environmental Protection and the Pan American Health Organisation.

A recent assessment of the current situation in Barbados with respect to antimicrobial resistance pointed out the need for improved management with respect to antibiotics in healthcare settings, prevention of the spread of drug-resistant micro-organisms, elimination of the use of medically-important antibiotics for promoting growth in livestock, and expanded surveillance for drug-resistant bacteria in humans and animals.

I am sure that as a result of this action plan, appropriate health promotion on antimicrobial medicines would be put in place. This will be combined with strategic surveillance and research, resulting in the desired outcome of optimal use of antimicrobial medicines and a reduction in the incidence of antimicrobial resistance in humans and animals in Barbados. The realisation of these desired outcomes will require sustained and coordinated efforts of the oversight committee headed by the Ministry of Health.

I therefore want to express my gratitude to all of those who contributed to the development of this plan. It proposes actions which will help to further strengthen health care delivery in Barbados. I pledge my full support to this plan and eagerly look forward to its implementation.

**Honourable John DE Boyce,**

  
Minister of Health

## Contents

Acknowledgements .....	3
Abbreviations .....	4
Introduction.....	6
Background.....	6
Alignment with AMR global action plan.....	6
Multi-sectoral systems approach.....	7
Strategic Vision.....	8
Vision .....	8
Scope of the National Action Plan .....	8
Governance.....	8
Current Country Situation .....	8
Summary of Assessment.....	9
Goals of the National Action Plan.....	10
Objectives of the National Action Plan.....	11
Table 1: Operational Framework for Objectives .....	12
Objective 1: Improve awareness and understanding of antimicrobial resistance through effective communication, education and training.....	14
Objective 2: Strengthen the knowledge and evidence base through surveillance and research. ....	18
Objective 3: Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures. ....	22
Objective 4: Optimize the use of antimicrobial medicines in human and animal health.....	25
Objective 5: Develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new interventions.....	29
National Targets to Combat Antibiotic Resistant Bacteria.....	30
Appendices.....	31
Appendix 1: Drafting Team for AMR Plan.....	31
Appendix 2: List of Contributors.....	32
Appendix 3: Terms of Reference for AMR Oversight Committee.....	33
Appendix 4: WHO AMR Pathogens and Types of Resistance of Concern .....	34
Bibliography.....	35

**Acknowledgements**

The contributions of the following Organisations, Departments and Ministries to the completion of this plan is gratefully acknowledged: Environmental Protection Department, Ministry of Environment and Drainage; Barbados Drug Service, Ministry of Health; The Queen Elizabeth Hospital, Barbados; Veterinary Services, Ministry of Agriculture; Public Health Laboratory, Ministry of Health; and Pan American Health Organization.

## **ABBREVIATIONS**

AMR	Antimicrobial Resistance
AMS	Antimicrobial Stewardship
BAMP	Barbados Association of Medical Practitioners
BARP	Barbados Association of Retired Persons
BDA	Barbados Dental Association
BDS	Barbados Drug Service
BNA	Barbados Nurses Association
CAO	Chief Agricultural Officer
CARPHA	Caribbean Public Health Agency
COHSOD	Council for Human and Social Development
CLO	Chief Labour Officer
CME	Continuing Medical Education
CMO	Chief Medical Officer
CRS	Caribbean Regulatory System
CSA	Country Situation Analysis
CVO	Chief Veterinary Officer
EPD	Environmental Protection Department
FAO	Food and Agriculture Organization of the United Nations
GAP	Global Action Plan
GAS	Government Analytical Services
GC	Neisseria gonorrhoea
IPC	Infection Prevention and Control
MA	Ministry of Agriculture, Food, Fisheries and Water Resources Management
MED	Ministry of the Environment and Drainage
MH	Ministry of Health
MT	Ministry of Tourism

MIICSBD	Ministry of Industry, International Business, Commerce and Small Business Development
MRSA	Methicillin Resistant Staphylococcus aureus
NAHFCP	National Agricultural, Health and Food Control Programme
NAP	National Action Plan
OIE	World Organization for Animal Health
PAHO	Pan American Health Organization
PHL	Public Health Laboratory
QEH	Queen Elizabeth Hospital
SMOH(N)	Senior Medical Officer of Health (N)
TCDPO	Town and County Development and Planning Office
UWI	University of the West Indies
VRE	Vancomycin Resistant Enterococcus
WHA	World Health Assembly
WHO	World Health Organization

## INTRODUCTION

### Background

For several decades, antimicrobial resistance (AMR) has been a growing threat to effective treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi. AMR results in reduced efficacy of antibacterial, anti-parasitic, antiviral and antifungal drugs, making the treatment of patients difficult, costly, or even impossible. The impact on particularly vulnerable patients is most obvious, resulting in prolonged illness and increased mortality. The magnitude of the problem worldwide and the impact of AMR on human health, on costs for the health-care sector and the wider society are still largely unknown. (*WHO, 2014*) In response to this developing public health issue, a global action plan on antimicrobial resistance has been developed and at the 68<sup>th</sup> World Health Assembly in May 2015, Member States approved the resolution to implement the Global Action Plan (GAP). (*WHO, WHA decision point: WHA A/68/20, A68/VR/9, May 2015*) The GAP embraces the ‘One Health’ concept for integrated management of AMR in the food chain.

Notably, Member States agreed on the importance of moving forward to develop national action plans by May 2017. These plans would be aligned with the GAP for the use of antimicrobial medicines in animal health, agriculture and human health. (*WHO, Global Action Plan for Antimicrobial Resistance (GAP-AMR), 2015*)

This National Action Plan on Combatting AMR was influenced by a national multi-sectoral stakeholder consultation which included representatives from government, the private sector, University of West Indies and non-governmental organizations. It conforms to the principles of the National Strategic Plan 2006-2025 especially in goal 4 which speaks to preserving a healthy environment and the Barbados Growth and Development Strategy 2013 – 2020 which addresses the sustainable production of safe food through agriculture and fisheries production and the protection and maintenance of human health throughout the life course.

### Alignment with AMR global action plan

The goal of the Global Action Plan for Antimicrobial Resistance (GAP-AMR) is: “To ensure, for as long as possible, continuity of successful treatment and prevention of infectious diseases with effective and safe medicines that are quality-assured, used in a responsible way, and accessible to all who need them”.

The five (5) Strategic Objectives of the GAP-AMR are:

- Objective 1: Improve awareness and understanding of antimicrobial resistance through effective communication, education and training.
- Objective 2: Strengthen the knowledge and evidence base through surveillance and research.
- Objective 3: Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures.
- Objective 4: Optimize the use of antimicrobial medicines in human and animal health.
- Objective 5: Develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions.

In particular, all action plans should reflect the following principles identified in the GAP:

1. Whole-of society engagement including “One Health” approach
2. Prevention first
3. Access
4. Sustainability
5. Incremental Targets for implementation

### **Multi-sectoral systems approach**

Ensuring ownership of activities across the sectors of health, agriculture, food security, animal health and economic development, is essential to achieve the desired outcome of containing antimicrobial resistance. The “One Health” approach acknowledges that the health of humans is directly linked to the health of animals and the environment.



## STRATEGIC VISION

### Vision

Integrated health care systems in Barbados that by 2027, work to prevent, detect, and control illness and death related to infections caused by antimicrobial resistance through shared responsibility whilst ensuring sustainable medical care.

### Scope of the National Action Plan

Antimicrobial resistance encompasses resistance to drugs utilized in the treatment of infections caused by different types of pathogenic organisms. This *National Action Plan*, will mainly focus on resistant bacteria that present an urgent or serious threat to public health. This plan will serve as a guide for partners in human, veterinary and environmental health to address this problem.

### Governance

Development and implementation of the *National Action Plan* will be guided by an inter-sectoral coordinating mechanism named the National Antimicrobial Oversight Committee, with Terms of Reference as at Appendix 3. The Ministry of Health will take the lead in this initiative and the oversight Committee will comprise but not be limited to representatives from the following areas and departments: National Epidemiology/Surveillance, Health Promotion, Infection Prevention and Control, Barbados Drug Service, Laboratories, Agriculture, Customs, Commerce, Environmental Protection Department and PAHO.

### Current Country Situation

Antibiotics are used in the health sector, (community and hospitals) the agricultural sector (livestock and cultivation) and are found in environmental media including ground, surface, marine and waste water.

Carbapenem-resistant *Klebsiella pneumonia* (CRKP), recently classified by WHO as a priority 1 resistant organism, was detected in a cluster of cases in the Queen Elizabeth Hospital (QEH) in 2013. Resultant active surveillance of cultures to assess the burden of CRKP at the QEH, revealed that 18% of patients sampled were either infected or colonised by CRKP. Specific antibiotics, flouroquinolones and piperacillin-tazobactam, were significantly associated with infection/colonization. In 2014, the 12 month period prevalence of CRKP in Barbados was 50 per 100, 000 population and incidence of blood stream infection was 4 per 100,000 population (QEH, 2013).

In the two year period 2015- 2017 at the Veterinary Services Laboratory, clinical and surveillance isolates from varying organ systems in varied domestic animals – dogs, horse, parrot and a primate, revealed a small number (11 cases) of multi-drug resistance. Gram positive and gram negative bacteria were identified in which resistance was detected over a

wide class of antimicrobial agents inclusive of aminoglycosides, cephalosporins, macrolides, penicillins, phenicols, polypeptides, quinolones, sulphonamides and tetracyclines (Personal communication, VSL).

The National Antibiotic Resistance Study conducted in 2013 assessed fifty-eight (58) sample sites which included twenty-two (22) public supply wells, eighteen (18) bathing water beaches, one (1) water treatment plant, two (2) sewage treatment plants, three (3) agricultural wells, three (3) surface water sites and nine (9) polyclinics to determine if faecal coliforms had developed resistance to selected antibiotics. The study indicated that there was no significant resistance noted in these groups in E. coli and enterococcus. In addition no Carbapenem resistance in Klebsiella was found or 3rd generation resistance suggesting ESBLs. (EPD 2015).

In the human health sector, a portion of antibiotic and other antimicrobial drug use is guided by the Barbados Drug Service (BDS) through the annual publishing of the National Drug Formulary. However, there are other antimicrobials available which are not on formulary.

Current ability to test and register antimicrobials for use in human and animals is limited. Incomplete, inappropriate and uncontrolled use of antimicrobials is thought to be the major driver of antimicrobial resistance in Barbados.

Surveillance systems for AMR are present but inconsistent, with few or no reporting systems. There is also rudimentary laboratory capacity for AMR testing and monitoring in Barbados and the Caribbean.

Knowledge of AMR amongst health care workers is limited to areas surrounding infection control in health care settings. There is also an element of over-prescribing and dispensing of antimicrobial medicines and the issue of incomplete treatment courses of antimicrobials.

The current legislation for antimicrobials comprises the Therapeutic Substances Act, Cap 330 and the Therapeutic Substances Regulations, 1950. The Act seeks to regulate the manufacture, importation, storage, sale and supply of penicillin and other antibiotics, and of sulphonamide drugs and other therapeutic substances through a licence granted by the Licensing Authority, the Chief Medical Officer. However, the Regulations exempt any preparation which is to be used solely for veterinary purposes.

## **Summary of Assessment**

Barbados currently has a rudimentary framework and capacity to address the issue of antimicrobial resistance. There however needs to be coordination of efforts and improvement in areas where gaps have been identified. Actions required include improved antibiotic stewardship in healthcare settings, prevention of the spread of drug-resistant organisms//bacteria, elimination of the use of medically-important antibiotics for growth promotion in food animals, and expanded surveillance for drug-resistant bacteria in humans and animals.

The *National Action Plan* will provide the roadmap to guide Barbados in the effort to address the urgent and serious threat of AMR and will be organized around three goals for collaborative action.

## **Goals of the National Action Plan**

The three (3) Goals of the NAP are:

- Goal 1: Slow/Reduce the emergence of resistant bacteria and prevent the spread of resistant infections.
- Goal 2: Strengthen national “One-Health” surveillance efforts to combat resistance
- Goal 3: Improve international collaboration and capacities for antimicrobial resistance prevention, surveillance, control and antibiotic research and development.

**Goal 1: Slow/Reduce the emergence of resistant bacteria and prevent the spread of resistant infections.** Judicious use of antibiotics in healthcare and agricultural settings is essential to slow the emergence of resistance and extend the useful lifetime of effective antibiotics. Antibiotics are a precious resource, and preserving their usefulness will require cooperation and engagement by healthcare providers, healthcare leaders, pharmaceutical companies, veterinarians, the agricultural industry, and patients. Goal 1 activities include the optimal use of vaccines to prevent infections, implementation of healthcare policies and antibiotic stewardship programs that improve patient outcomes, and efforts to minimize the development of resistance by ensuring that each patient receives *the right antibiotic at the right time at the right dose for the right duration*. Prevention of resistance also requires rapid detection and control of outbreaks and regional efforts to control transmission across community and healthcare settings and international borders.

**Goal 2: Strengthen national “One-Health” surveillance efforts to combat resistance.** Improved detection and control of drug-resistant organisms will be achieved through an integrated, “One-Health” approach that includes the enhancement and integration of data from surveillance systems that monitor human pathogens with data that monitor animal pathogens. Goal 2 activities will enhance monitoring of antibiotic sales, usage, resistance, and management practices at multiple points along the food-production chain, from farms to processing plants to supermarkets.

**Goal 3: Improve international collaboration and capacities for antimicrobial resistance prevention, surveillance, control and antibiotic research and development.** Antibiotic resistance is a worldwide problem that cannot be addressed by one nation in isolation. Goal 3 activities include working with foreign ministries of health and agriculture, the World Health Organization (WHO), the Food and Agriculture Organization (FAO), the World Organization for Animal Health (OIE), and other multinational organizations to enhance global capacity to detect, analyze, report antibiotic use and resistance, create incentives for the development of therapeutics and diagnostics, and strengthen global efforts to prevent and control the emergence and spread of antibiotic-resistance.

## **Objectives of the National Action Plan**

In alignment with those of the GAP-AMR, the five (5) Objectives of the NAP are:

- Objective 1: Improve awareness and understanding of antimicrobial resistance through effective communication, education and training.
- Objective 2: Strengthen the knowledge and evidence base through surveillance and research including in animals, plants, the environment and food.
- Objective 3: Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures.
- Objective 4: Optimize the use of antimicrobial medicines in human and animal health.
- Objective 5: Develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new medicines, diagnostic tools, vaccines and other interventions.

**Table 1: Operational Framework for Objectives**

No.	Objective	Operational Framework	Timeframe
1	Improve awareness and understanding of antimicrobial resistance through effective communication, education and training.	<p><b><u>Risk Communication:</u></b></p> <ol style="list-style-type: none"> <li>1. Develop a national communication strategy for AMR.</li> <li>2. Engage and educate policy makers.</li> <li>3. Develop advocacy materials for the general public, policy makers and health care providers.</li> </ol> <p><b><u>Education:</u></b></p> <ol style="list-style-type: none"> <li>1. Develop guidelines for health care professionals on AMR (including IPC, rational use of antimicrobial medicines, surveillance, etc.) and implement in-service training.</li> <li>2. Include antimicrobial use and resistance in the curricula across all levels of education.</li> </ol>	2017-2019
2	Strengthen the knowledge and evidence base through surveillance and research.	<p><b><u>National AMR Surveillance System:</u></b></p> <ol style="list-style-type: none"> <li>1. Identify/Establish a national entity with the ability to systematically collect, analyse and report data on AMR from all sources so as to inform decision-making at national and international levels.</li> <li>2. Establish mechanisms for regular information sharing on AMR data across human health, animal health and environmental sectors.</li> </ol> <p><b><u>Laboratory Capacity:</u></b></p> <ol style="list-style-type: none"> <li>1. Enhance laboratory capacity to ensure capability of quality assured identification and susceptibility testing and reporting, including on newly emerged resistance.</li> <li>2. Ensure that all national laboratories are involved in external quality assurance (EQA) programs.</li> </ol> <p><b><u>Research:</u></b></p> <ol style="list-style-type: none"> <li>1. Identify operational research priorities for promoting responsible use of antimicrobial medicines; defining improved practices for preventing infection in human and animal health and agricultural practice.</li> </ol>	<p>2017-2019</p> <p>2017- 2022</p> <p>2017-2020</p>
3	Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures.	<p><b><u>Community Level Prevention:</u></b></p> <ol style="list-style-type: none"> <li>1. Promote good hand hygiene and personal hygiene practices through social mobilization and behaviour change activities.</li> <li>2. Promote vaccination among the public and health care providers.</li> <li>3. Promote universal waste water treatment and improve waste disposal practices</li> </ol>	2017-2020

No.	Objective	Operational Framework	Timeframe
		<b><u>IPC in Health Care Settings:</u></b> <ol style="list-style-type: none"> <li>1. Update national policies and plans for biomedical waste management, including safe collection, storage, transportation and final disposal.</li> <li>2. Develop and implement national IPC programs.</li> <li>3. Establish/Strengthen IPC programs in health care facilities, particularly tertiary hospitals.</li> </ol>	2017-2019
		<b><u>Animal Health</u></b> <ol style="list-style-type: none"> <li>1. Strengthen animal health and agricultural practices through implementation of standards to minimize and contain AMR.</li> <li>2. Promote vaccination as a method of reducing infections in food animals.</li> </ol>	2018-2021
		<b><u>Environmental Health</u></b> <ol style="list-style-type: none"> <li>1. Develop a policy on collection and disposal of obsolete (expired, unknown, banned) drugs.</li> <li>2. Implement updated ground water protection policy.</li> <li>3. Regulate Wastewater Reuse practices.</li> </ol>	2018-2020
4	Optimize the use of antimicrobial medicines in human and animal health.	<b><u>Access to quality antimicrobial medicines:</u></b> <ol style="list-style-type: none"> <li>1. Develop and enforce legislation and regulations on prescribing and dispensing of antimicrobials</li> <li>2. Strengthen pharmaceutical supply chain (procurement, supply and quality management).</li> <li>3. Strengthen/Establish mechanisms for registration of antimicrobial medicines within relevant national authorities.</li> <li>4. Establish national mechanisms (e.g. market surveillance), which link with global mechanisms for identification and reporting on sub-standard, spurious, falsely labelled, falsified, or counterfeit medicines.</li> <li>5. Develop and enforce guidelines regarding promotional practices –of the industry.</li> <li>6. Develop and implement evidence- based standard treatment protocols to guide stewardship programs in human health.</li> <li>7. Develop and implement a national and institutional essential antimicrobial medicines list.</li> </ol>	2017-2022
		<b><u>Animal Health Sector:</u></b> <ol style="list-style-type: none"> <li>1. Identify and limit use of antibiotics in the animal sector for non-therapeutic purposes.</li> </ol>	2018-2022



	<p>Permanent Secretaries</p> <p>Sensitization of Cabinet and Social Partners. Cabinet presentation including Budget</p>			Oversight Committee
<p>Develop advocacy materials for the general public, policy makers and health care providers. (human and animal), farmers, retailers) For all stake holders (general workers</p>	<ul style="list-style-type: none"> <li>Conduct a national public education campaign regarding the use of antimicrobial drugs and issues of antimicrobial resistance. (AMR week)</li> <li>Engage the health professional bodies (Barbados Association of Medical Practitioners, Barbados Nurses Association, Barbados Dental Association, Veterinary Council, Barbados etc.) as well as the Barbados Agricultural societies and other relevant stakeholders</li> <li>Develop materials and media to target farmers, retailers, and commerce regarding AMR issues</li> </ul>	Not in place	November 2018	<p>Senior Health Promotion Officer, Ministry of Health</p> <p>Data provided to SHPO for schools, GIS, METI to create booklet, brochures, jingles etc., social media (facebook, Instagram, whatsapp). Regularly updated website. Presentations to different social groups – through polyclinics to churches, PTA etc.</p> <p>PAHO/Barbados Retired Nurses association/UWI CME, BAMP bulletins, joint seminars and workshops (MH, MA, METI). Presentations in quarterly laboratory meetings for laboratory staff.</p>



	<ul style="list-style-type: none"> <li>• Develop Poster, logo and Slogan competitions</li> <li>• develop targeted messages <sup>1</sup>e.g tourism, agriculture, consumers, public, children, using</li> <li>• Social media</li> <li>• Jingles</li> <li>• Video</li> <li>• Skits ...laff it off, Rum &amp; Koke</li> </ul>			
--	--	--	--	--

<b>Education</b>				
<b>Interventions</b>	<b>Activities</b>	<b>Current Situation</b>	<b>Timeframe</b>	<b>Lead</b>
Develop guidelines for health care professionals on AMR (including IPC, rational use of antimicrobial medicines, surveillance, etc.) and implement in-service training.	<ul style="list-style-type: none"> <li>• Sensitization of health care workers through CME accredited courses on AMR and Antimicrobial Stewardship, through workshops and issuing of supporting educational material.</li> <li>• HIC - Free webinars, Online course on AMS</li> </ul>	Started in public sector. Needs to be continued and extended to the private health sector.	2018  Dec2017 (depending on schedule of trainers)	NICC
Develop guidelines for disposal of unused, expired, spurious, substandard, falsified, falsely labelled and counterfeit antimicrobials	<ul style="list-style-type: none"> <li>• Sensitive public re need for guidelines</li> <li>• Sensitize various stakeholders (environmental health, SSA, etc) using various media.</li> </ul>	Do not exist		

<sup>1</sup>Messages should include Mode of Transmission etc.

Include antimicrobial use and resistance in the curricula across all levels of education.	<ul style="list-style-type: none"> <li>Engage Medical and Nursing Schools pharmacy, agricultural, environmental health, hospitality training schools, vets (University of the West Indies, Barbados Community College, SJPP, Barbados Veterinary Association etc.).</li> <li>Engage Ministry of Education regarding Agricultural science curricula</li> </ul>	Started	Jan 2018	SMOH(N) with UWI, BCC rep
---	---	---------	----------	---------------------------

## Objective 2: Strengthen the knowledge and evidence base through surveillance and research.

Develop a national surveillance system for antimicrobial resistance				
Interventions	Activities	Current Situation	Timeframe	Lead
<p>Identify/Establish a national entity with the ability to systematically collect, analyse and report data on AMR from all sources to facilitate informed decision-making at national and international levels</p>	<ul style="list-style-type: none"> <li>Expand and strengthen the infrastructure of the Ministry of Health's Surveillance Unit to oversee the AMR surveillance program, including collecting, aggregating and sharing data using a secured central database.</li> </ul>	Only Carbapenem-Resistant Klebsiella Pneumoniae (CRKP) data received. Need others - MRSA, VRE, GC	Dec 2017	SMOH(N)
	<ul style="list-style-type: none"> <li>Expand and strengthen the infrastructure of the Ministry of Health's Surveillance Unit to identify what data needs to be reported from the sources.</li> </ul>	Only enteric pathogens, Dengue and Malaria are reported.	May 2018	SMOH(N)
	<ul style="list-style-type: none"> <li>Determine sample sources (all labs or sentinel labs – samples or pathogens – refer to WHO AMR guidelines)</li> </ul>	Not currently performed	May 2018	SMOH (N)
	<ul style="list-style-type: none"> <li>Determine the antimicrobials and pathogens important to Barbados.</li> <li>Expand and strengthen the national infrastructure for public health</li> </ul>			CVO
				CVO

	<p>surveillance and data reporting, and provide incentives for timely reporting of antibiotic-resistance and antibiotic use in all healthcare settings.(official correspondence from MH to all private and public medical facilities on reportable pathogen inclusive of list of all reportable pathogens)</p> <ul style="list-style-type: none"> <li>• Develop and publish annual antibiograms and reports on AMR.</li> <li>• Enhance collection and reporting of data regarding antibiotic drugs sold and distributed for use in food-producing animals.</li> <li>• Annual publication of enhanced summary reports on the sale and distribution of antibiotics approved for use in food-producing animals.</li> </ul>	<p>Not currently performed</p> <p>Not currently performed</p> <p>Not currently performed</p>	<p>Feb 2018</p> <p>Feb 2018</p> <p>Feb 2018</p>	
Establish mechanisms for regular information sharing on AMR data across human health, animal health and	<ul style="list-style-type: none"> <li>• Involve Ministry of Agriculture at Ministry of Health weekly surveillance meetings.</li> <li>• Involve Ministry of Environment</li> </ul>	<p>Not currently performed</p> <p>Started in July 2015.</p>	Feb 2018	Surveillance Unit

environmental sectors.	<p>at Ministry of Health and QEH weekly surveillance meetings.</p> <ul style="list-style-type: none"> <li>Commence quarterly laboratory meetings between the Public Health, QEH and the Veterinary and Government Analytical Laboratories and private labs.</li> </ul>	Not currently performed	June 2017	<p>Surveillance Unit</p> <p>Consultant Microbiologist QEH</p>
------------------------	--	-------------------------	-----------	---

<b>Improve Laboratory capacity</b>				
<b>Interventions</b>	<b>Activities</b>	<b>Current Situation</b>	<b>Timeframe</b>	<b>Lead</b>
Enhance laboratory capacity to ensure capability of quality assured identification and susceptibility testing and reporting, including on newly emerged resistance.	<ul style="list-style-type: none"> <li>Develop, expand, and maintain capacity in veterinary and food safety laboratories to conduct standardized antibiotic susceptibility testing and characterize select zoonotic and animal pathogens.</li> <li>Accreditation of the Veterinary and Government Analytical Laboratories is required.</li> <li>Improve processes through standardization at the Queen Elizabeth Hospital and Public Health Laboratories for antibiotic susceptibility testing.</li> <li>Introduction of the testing for MIC's on a routine basis for</li> </ul>	<p>Vet Labs – currently performed</p> <p>In progress</p> <p>Completed for public laboratories, not private labs</p> <p>In progress</p>	<p>2022</p> <p>Dec 2017</p> <p>2017</p>	<p>Lab Manager, VSL</p> <p>Director, GAS</p> <p>Lab Manager, VSL</p> <p>Pathology Laboratory Advisory Committee</p> <p>Consultant Microbiologist</p>



**Objective 3: Reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures.**

<b>Community level prevention</b>				
<b>Interventions</b>	<b>Activities</b>	<b>Current Situation</b>	<b>Timeframe</b>	<b>Lead</b>
Promote hand hygiene and good personal hygiene practices through social mobilization and behaviour change activities.	<ul style="list-style-type: none"> <li>Strengthen national public education campaign to promote hand washing and good personal hygiene <sup>2</sup></li> </ul>	<ul style="list-style-type: none"> <li>Currently outbreak specific</li> <li>Currently season specific</li> </ul>	Quarterly over plan life	Senior Health Promotion Officer, Ministry of Health
Promote vaccination among the public and health care providers.	<ul style="list-style-type: none"> <li>Conduct vaccination promotion campaigns Identifying and integrating the linkages between vaccines and the importance of preventing AMR</li> </ul>	Not currently in practice	Annually commencing 2017	Senior Health Promotion Officer, Ministry of Health and Expanded Program on Immunization (EPI) Manager

<b>Strengthen infection prevention and control in Health Care Settings</b>				
<b>Interventions</b>	<b>Activities</b>	<b>Current Situation</b>	<b>Timeframe</b>	<b>Lead</b>
Update national policies and plans for biomedical waste management, including safe collection, storage, transportation and final disposal.	<ul style="list-style-type: none"> <li>Continue the work of the National Biomedical Waste Management Committee which was established in 2011.</li> </ul>	Implementation of protocols to be continued.	2018	MH and EPD
Develop and implement national IPC programs.	Continue the work of the National Infection Prevention and Control Committee was established in March 2014.	Work commenced.		MH, CAO, CLO. Unions

<sup>2</sup>Message needs to be specific to target groups

	<ul style="list-style-type: none"> <li>Integrate ICP as a requirement for issuing of institutional Health licence under the Health Services (Private Hospitals, Nursing Homes, Senior Citizens' Homes and Maternity Homes) Regulations, 2005.</li> <li>Institute continuous education programs for all categories of staff</li> <li></li> </ul>	Not currently performed		
Establish/Strengthen IPC programs in health care facilities, particularly tertiary hospitals.	<ul style="list-style-type: none"> <li>A Polyclinic Committee on IPC has been established as an arm of the National IPC Committee.</li> <li>Continue training of health care workers in IPC.</li> <li>Link IPC knowledge management with Key performance indicators and performance appraisal systems</li> </ul>	Work commenced.  Not currently performed	2019	MH, , CAO, CLO. Unions

<b>Animal Health</b>				
<b>Interventions</b>	<b>Activities</b>	<b>Current Situation</b>	<b>Timeframe</b>	<b>Lead</b>
Strengthen animal health and agricultural practices through implementation of standards to minimize and contain AMR.	<ul style="list-style-type: none"> <li>Conduct a national awareness program to increase sanitation on agri-enterprises</li> <li>Introduce a trace-back program</li> <li>Develop a legal framework for the importation of animal antibiotics</li> </ul>	Currently not in place	2019	MA NAHFCP



Promote vaccination as a method of reducing infections in food animals.	<ul style="list-style-type: none"> <li>Foster collaborations and public-private partnerships with public health, pharmaceutical, and agricultural stakeholders to facilitate identification and implementation of interventions (e.g., good husbandry practices) to reduce the spread of antibiotic resistance.</li> <li>Develop a system for monitoring Antibiotic in Animal feeds</li> </ul>	Not currently in place	2022	MA NAHFCP
		Not currently in place	2019	MA, Commerce
<b>Environmental Health</b>				
<b>Interventions</b>	<b>Activities</b>	<b>Current Situation</b>	<b>Timeframe</b>	<b>Lead</b>
Develop a policy on collection and disposal of obsolete (expired, unknown, banned) drugs	<ul style="list-style-type: none"> <li>Develop a legal framework to make distributors primarily responsible for obsolete drugs</li> <li>Establish take-back programs</li> <li>Evaluate obsolete drug disposal options (landfilling, incineration, shipping overseas)</li> <li>Improve incineration capacity and treatment capability</li> </ul>	Not Currently in place	2020	MH, MED
		Currently not in place	2021	MH
		Currently not in place	2019	MH, MED
		In progress		MH

Implement updated ground water protection policy	<ul style="list-style-type: none"> <li>Finalise and implement the updated groundwater protection policy</li> </ul>	On going	2018	BWA, EPD, TCDPO
	<ul style="list-style-type: none"> <li>Improve wastewater treatment capacity for sewage sludge</li> </ul>	On going	2018	
Regulate wastewater reuse Practices	<ul style="list-style-type: none"> <li>Finalise the Water Reuse Policy.</li> <li>Establish a legal frame work for wastewater reuse</li> </ul>	On going	2017	EPD, BWA, BNSI, EHD, TCDPO
		No current framework	2019	

#### **Objective 4: Optimize the use of antimicrobial medicines in human and animal health.**

<b>Access to quality antimicrobial medicines</b>				
<b>Interventions</b>	<b>Activities</b>	<b>Current Situation</b>	<b>Timeframe</b>	<b>Lead</b>
Develop and enforce legislation and regulations on prescribing and dispensing of antimicrobials.	<ul style="list-style-type: none"> <li>Implement annual reporting of antibiotic use in inpatient and outpatient settings and identify geographic variations and/or variations at the provider and/or patient level that can help guide interventions.</li> <li>Update legislation for dispensing practices for human and animal health</li> </ul>	<p>Limited reporting on antibiotic use in public sector and no reporting in private sector.</p> <p>Therapeutic Licence is required for import of all antimicrobials including antibiotics &amp; antifungals; once on island there is no tracking of usage</p>	2017- 2022	MH MA MC
Strengthen pharmaceutical supply chain	<ul style="list-style-type: none"> <li>To establish a system for the disposal of</li> </ul>	Health Services (Control of	2017-2019	BDS EPD

(procurement, supply and quantity management).	expired/unused drugs (Animal and Human health).	Drugs) Regulations, 1970 includes a Destruction of Drug Certificate which is issued by Drug Inspectors on request, from all places which store and issue drugs		
Strengthen/Establish mechanisms for registration of antimicrobial medicines within relevant national authorities.	<ul style="list-style-type: none"> <li>Institute a system to regulate the importation and use of veterinary drugs.</li> </ul>	<p>No present system</p> <p>All drugs to be registered through CRS/ CARPHA</p> <p>The Therapeutic Substances Act CAP.30 - An Act to regulate the manufacture, importation, storage, sale and supply of penicillin and other antibiotics, and of sulphonamide drugs and other therapeutic substances.</p>	2017-2020	Vet Services MA
Establish national mechanisms (e.g. market surveillance) which link with global mechanisms for identification and reporting on sub-standard, spurious falsified, falsely labelled, and	<ul style="list-style-type: none"> <li>Strengthen pharmacovigilance programme.</li> <li>Review - and amend where necessary - existing legislation regarding sub-standard, spurious, falsified, falsely labelled, and</li> </ul>	There is a pharmacovigilance program in place; it however needs to be more utilised by stakeholders.	2017-2018	BDS MC

counterfeit medicines.	counterfeit mechanisms.			
Develop and enforce guidelines regarding promotional practices of the industry	<ul style="list-style-type: none"> <li>Research and review governing legislation</li> </ul>	Present Legislation: Health Service (Control of Drugs) Regulations Subsection 4	2017- 2019	BDS, Solicitor General
Develop and implement evidence based standard treatment guidelines protocols to guide stewardship programs.	<ul style="list-style-type: none"> <li>Strengthen antibiotic stewardship in inpatient, outpatient, and long-term care settings by expanding existing programs, developing new ones, and monitoring progress and efficacy.</li> <li>Identify and implement measures to foster stewardship of antibiotics in animals.</li> <li>Develop and conduct educational programs that inform physicians, veterinarians, members of the agricultural industry, and the public about good antibiotic stewardship.</li> </ul>	<p>Inpatient (QEH) mechanism exists; no system for outpatient monitoring</p> <p>Nothing currently in place. Materials presently being developed</p> <p>Programme has started</p> <p>Surveillance system for drug residues in food to be developed</p>	2017- 2019	
Develop and implement a national and institutional essential medicine list.	<ul style="list-style-type: none"> <li>Ensure clinicians receive up-to-date and timely antibiotic susceptibility data to guide antibacterial drug selection.</li> </ul>	Currently there is a  <b>“Criteria governing the prescribing of antibiotics</b>	2017-2018	

	<ul style="list-style-type: none"> <li>• Collaboration with all laboratories, polyclinics, hospital, district hospitals to develop list with reference to known antimicrobial susceptibilities with antibiogram</li> <li>• Develop mechanism to issue list as needed to stakeholders.</li> </ul>	<p><b>on the Barbados National Drug Formulary”</b> statement in the BNDF</p> <p>Process had previously been started by the Queen Elizabeth Hospital (update needed)</p>		BDS
--	--	---	--	-----

<b>Regulate access to antimicrobial medicines in Animal Health</b>				
<b>Interventions</b>	<b>Activities</b>	<b>Current Situation</b>	<b>Timeframe</b>	<b>Lead</b>
<ol style="list-style-type: none"> <li>1. Identify and limit the use of antibiotics in the animal sector for non-therapeutic purposes</li> <li>2. Establish a list and suppliers of antibiotics formulated for animal use</li> <li>3. All local and imported feeds MUST be antibiotic free</li> </ol>	<ul style="list-style-type: none"> <li>• Assessment of current situation</li> <li>• Prepare technical guidelines for the appropriate legislation</li> <li>• Draft legislation by CPC</li> <li>• Eliminate the use of antibiotics for growth promotion in food- producing animals and bring other agricultural uses of antibiotics, for treatment, control, and prevention of disease, under veterinary oversight.</li> <li>• Request MC to institute requirement of import licences for animal feed</li> </ul>	No present legislation	<p>2017-2022</p> <p>2017-2018</p>	Veterinary Services

**Objective 5: Develop the economic case for sustainable investment that takes account of the needs of all countries, and increase investment in new interventions.**

<b>Interventions</b>	<b>Activities</b>	<b>Current Situation</b>	<b>Timeframe</b>	<b>Lead</b>
Assess the investment needs for implementation of the NAP.	<ul style="list-style-type: none"> <li>Solicit 'buy in' from CARICOM through its regional agencies. Present to COHSOD and annual regional meeting of Ministers of Health</li> </ul>		2017-2019	MH, PAHO
Secure local funding for implementation of Antimicrobial Action Plan	<ul style="list-style-type: none"> <li>Request a line item in the annual estimates of expenditure</li> </ul>	No line item	2018-2019	MH/MOF&EA MA
Consider and establish procedures for participation in international collaborative research to support the development of new medicines, diagnostic tools and vaccines.	<ul style="list-style-type: none"> <li>Develop international collaborations to gather country-specific and regional information on drivers of antibiotic resistance, identify evidence-based interventions, adapt these strategies to new settings, and evaluate their effectiveness.</li> <li>Collaborate with WHO, OIE, and other international agencies focused on the development of integrated, laboratory-based surveillance to detect and</li> </ul>	<p>No baseline data available</p> <p>Limited collaboration</p>	<p>2018-2020</p> <p>2017-2019</p>	<p>UWI /MH</p> <p>MH, VSL WHO/PAHO</p>

	monitor antibiotic resistance in relevant animal and human foodborne pathogens.			
Invest in a sustainable vaccine programme including consideration for the agricultural sector	<ul style="list-style-type: none"> <li>Promote vaccines for vaccine preventable diseases e.g. influenza and season flu, measles</li> </ul>	ongoing	2017-2018	MH

The National oversight committee will work with allied agencies whenever necessary including the HIV/AIDs Programme and Tuberculosis Prevention and Control programme

## National Targets for Antibiotic Resistant Bacteria

Stabilise within 3 years and then demonstrate a yearly decline in the incidence of overall *Clostridium difficile* infection compared to estimates from 2011.

Stabilise within 3 years and then demonstrate a yearly decline in the rate of Carbapenem-resistant Enterobacteriaceae infections acquired during hospitalization.

Maintain the prevalence of ceftriaxone-resistant *Neisseria gonorrhoeae* below 2% compared to estimates from 2013.

Stabilise within 3 years and demonstrate a yearly decline in the rate of hospital acquired *Pseudomonas spp.* infections.

Stabilise within 3 years and demonstrate a yearly decline in methicillin-resistant *Staphylococcus aureus* (MRSA) bloodstream infections by 2020.

Stabilise within 3 years and demonstrate a yearly decline in multidrug-resistant non-typhoidal *Salmonella* infections compared to estimates from 2010-2012.

Maintain the occurrence of multidrug-resistant TB infections to 0% while maintaining alertness and cooperation through Tuberculosis Prevention Programme.

Determine the rate of antibiotic-resistant invasive pneumococcal disease among <5 year-olds over three years and based on this data establish a yearly decline as applicable.

Determine the rate of antibiotic-resistant invasive pneumococcal disease among >65 year-olds and based on this data establish a yearly decline as applicable.

## Appendices

### Appendix 1: Drafting Team for NAP on Combatting AMR 2017-2022

<b>Name</b>	<b>Organisation</b>
Denise Carter Taylor	Ministry of Health
Dr Kathy-Ann Clarke	Veterinary Services Laboratory
Dr Corey Forde	Queen Elizabeth Hospital
Mr Anthony Headley	Environmental Protection Department
Dr Rosina Maitland	Ministry of Agriculture
Dr Leslie Rollock	Ministry of Health
Ms Stephanie Sobers	Public Health Laboratory
Ms Cheryl-Ann Yearwood	Barbados Drug Service



## Appendix 2: List of Contributors

<b>Name</b>	<b>Organisation</b>
Dr Karen Springer	Ministry of Health
Dr Ingrid Cumberbatch	Ministry of Health
Dr Thais dos Santos	Pan American Health Organisation
Jorge Matheu	Pan American Health Organisation
Dr Jean Marie Rwangobwoba	Pan American Health Organisation
Dr Alexandra Vokaty	Pan American Health Organisation
Dr Marcelo Galas	Pan American Health Organisation
Dr Kenneth George	Ministry of Health
Denise Carter Taylor	Health Promotion Unit, Ministry of Health
Joy Springer	Government Information Service
Charmaine Blades	Surveillance Unit, Ministry of Health
Maria Ingram	Environmental Health Department, Ministry of Health
Hadley Bushell	IT Department, Queen Elizabeth Hospital
Stephanie Sobers	Public Health Laboratory, Ministry of Health
Lisa Reid	Laboratory, QEH
Dr Edmund Blades	Laboratory, QEH
Thora Osbourne	Barbados Reference Laboratory
Nathan Small	Government Analytical Laboratory
Dr Gittens-St Hilaire	Leptospirosis Laboratory, Ministry of Health
Kathy-Ann Clarke	Veterinary Services Laboratory
Anthony Headley	Environmental Protection Department
H/S Vickie Blackman	Polyclinics IPC, Ministry of Health
Dr Kimberley Phillips	Polyclinics IPC, Ministry of Health
Yvonne Martindale	IPC, QEH
Dr Corey Forde	IPC, QEH
Dr Delores Lewis	Barbados Association of Medical Practitioners
Dr Rosina Maitland	NAHFCP, Ministry of Agriculture
Dr Beverley Wood	NAHFCP, Ministry of Agriculture
Michael James	Ministry of Agriculture
Cheryl Yearwood	Barbados Drug Service
Dr Tracie Carmichael	Ladymeade Reference Unit, Ministry of Health
Margaret Campbell-Leslie	Department of Commerce & Consumer Affairs
Dr Leslie Rollock	Ministry of Health

### **Appendix 3: Terms of Reference for Oversight Committee of NAP on AMR**

To be agreed by Oversight Committee members

## Appendix 4: WHO AMR Pathogens and Types of Resistance of Concern

### WHO PRIORITY PATHOGENS LIST FOR R&D OF NEW ANTIBIOTICS

#### Priority 1: CRITICAL#

*Acinetobacter baumannii*, carbapenem-resistant

*Pseudomonas aeruginosa*, carbapenem-resistant

*Enterobacteriaceae*\*, carbapenem-resistant, 3rd generation cephalosporin-resistant

#### Priority 2: HIGH

*Enterococcus faecium*, vancomycin-resistant

*Staphylococcus aureus*, methicillin-resistant, vancomycin intermediate and resistant

*Helicobacter pylori*, clarithromycin-resistant

*Campylobacter*, fluoroquinolone-resistant

*Salmonella* spp., fluoroquinolone-resistant

*Neisseria gonorrhoeae*, 3rd generation cephalosporin-resistant, fluoroquinolone-resistant

#### Priority 3: MEDIUM

*Streptococcus pneumoniae*, penicillin-non-susceptible

*Haemophilus influenzae*, ampicillin-resistant

*Shigella* spp., fluoroquinolone-resistant

#*Mycobacteria* (including *Mycobacterium tuberculosis*, the cause of human tuberculosis), was not subjected to review for inclusion in this prioritization exercise as it is already a globally established priority for which innovative new treatments are urgently needed.

\* Enterobacteriaceae include: *Klebsiella pneumoniae*, *Escherichia coli*, *Enterobacter* spp., *Serratia* spp., *Proteus* spp., and *Providencia* spp, *Morganella* spp.

## **Bibliography**

1. WHO. (2014). *Antimicrobial Resistance Global Report on Surveillance*.
2. WHO. (2015). *Global Action Plan for Antimicrobial Resistance (GAP-AMR)*.
3. WHO. (May 2015). *WHA decision point: WHA A/68/20, A68/VR/9*.
4. Barbados National Strategic Plan 2006-2025
5. Barbados Growth and Development Strategy 2013-2020
6. QEH. (2013). CRKP Point Prevalence screening 2013 QEH Report prepared by the Infection Prevention & Control Department, QEH.
7. Environmental Protection Department, Barbados Water Authority, Public Health Laboratory, Environmental Health Department. (2015). "National Antibiotic Resistance Study: Prevalence of resistance in *Escherichia Coli*. and *Enterococcus* spp. Isolates from marine water, groundwater potable water, wastewater and environmental sources in Barbados".
8. Garry Struthers Associates Inc., Cooper Zietz Engineers, Janice Cumberbatch, Hospital Waste Management. ( 2005). "Consultancy to Design A Medical Waste Management System for Barbados". GOB/IBRD HIV/AIDS Prevention and Control, Project Loan No.: 7066-BAR. Prepared for the Government of Barbados, Ministry of Health, Sewerage and Solid Waste Unit, "Maxwelton", Collymore Rock, St. Michael, Barbados West Indies.
9. WHO. (2017). Priority Pathogens List for R&D of New Antibiotics